L. Baher

发表

Measurement of Amyloid-b Peptides in Cerebrospinal Fluid and Plasma Specimens from Patients with Alzheimer’s Disease Treated with Solanezu-

Nick C Fox, E. Liu, J. Seibyl, 2013 .

Within assay Between assay Within assay Between assay

E. Liu, J. Seibyl, B. Wyman, 2013 .

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Tom Chu, Peter W Angus, P. Angus, 2010, The Lancet.

749 EARLY ON-TREATMENT RESPONSES DURING PEGYLATED IFN PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1)

R. Elston, P. Angus, C. Stedman, 2010 .

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

R. Elston, P. Angus, C. Stedman, 2009 .

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Michael L. Wang, R. Advani, W. Jędrzejczak, 2015, Blood.

Oral combination therapy: Future hepatitis C virus treatment?

R. Elston, C. Stedman, W. Bradford, 2011 .